The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active incredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.

 
Web www.patentalert.com

< Small molecule inhibitors of rotamase enzyme activity

< Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents

> Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides

> Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
~ 00225